Profile Response Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org


Molecular Profile Unknown unknown
Therapy Enzalutamide + ZEN-3694
Indication/Tumor Type prostate cancer
Response Type not applicable

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown prostate cancer not applicable Enzalutamide + ZEN-3694 Preclinical - Cell culture Actionable In a preclinical study, ZEN-3694 in combination with Xtandi (enzalutamide) synergistically inhibited proliferation of an AR-positive prostate cancer cell line in culture (Cancer Res 2016;76(14 Suppl):Abstract nr LB-207). detail...
Unknown unknown prostate cancer not applicable Enzalutamide + ZEN-3694 Phase Ib/II Actionable In a Phase Ib/II trial, combination of ZEN-3694 and Xtandi (enzalutamide) demonstrated safety in metastatic castration-resistant prostate cancer patients resistant to prior androgen signaling inhibitors, and resulted in a median radiographic progression-free survival (rPFS) of 9.0 months and a composite median radiographic or clinical PFS of 5.5 months, patients with lower baseline AR activity demonstrated prolonged median rPFS (10.4 v 4.3 months) compared to patients with high AR activity (PMID: 32694156). 32694156
PubMed Id Reference Title Details
Preclinical characterization of ZEN-3694, a novel BET bromodomain inhibitor entering phase I studies for metastatic castration-resistant prostate cancer (mCRPC) Full reference...
(32694156) A Phase 1b/2a Study of the Pan-BET Bromodomain Inhibitor ZEN-3694 in Combination with Enzalutamide in Patients with Metastatic Castration Resistant Prostate Cancer. Full reference...